AstraZeneca/Targacept's TC-5214 to be DR's clinical 'Gold Standard' In 2013

Anglo-Swedish drug major AstraZeneca and partner Targacept's TC-5214 will earn Decision Resources' proprietary clinical 'gold standard' status in 2013 (following its approval that year) and through 2018.

Phase IIb trial results show significant improvement in Hamilton Depression Rating Scale scores on the effect on depressive symptoms in patients who did not respond adequately to citalopram monotherapy, noted DR. These results indicate that TC-5214 has competitive advantages in efficacy over current and emerging drugs for treatment resistant depression.

"Phase IIb trials demonstrated the efficacy of TC-5214 as an augmentation therapy for major depressive disorder; should Phase III trials demonstrate both efficacy and tolerability, TC-5214 will have a significant market advantage and may earn blockbuster sales in the major depressive disorder market," stated Decision Resources' analyst Alana Simorellis.